| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | Chief Business Officer | Employee Stock Option (right to buy) | 500,000 | 23 Feb 2023 | Direct | ||
| Alto Neuroscience, Inc. | CHIEF OPERATING OFFICER | Employee Stock Option (Right to Buy) | 131,000 | 11 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ANRO | Alto Neuroscience, Inc. | 11 Feb 2026 | 1 | $0 | 4 | CHIEF OPERATING OFFICER | 13 Feb 2026, 17:17 |
| ANRO | Alto Neuroscience, Inc. | 03 Jul 2025 | 6 | $0 | 4 | CHIEF OPERATING OFFICER | 08 Jul 2025, 17:22 |
| ANRO | Alto Neuroscience, Inc. | 05 Feb 2025 | 1 | $0 | 4 | CHIEF OPERATING OFFICER | 07 Feb 2025, 16:22 |
| ANRO | Alto Neuroscience, Inc. | 20 May 2024 | 1 | $0 | 4 | Chief Operating Officer | 22 May 2024, 17:19 |
| ANRO | Alto Neuroscience, Inc. | 20 May 2024 | 0 | $0 | 3 | Chief Operating Officer | 22 May 2024, 17:17 |
| SYRE | Aeglea BioTherapeutics, Inc. | 23 Feb 2023 | 1 | $0 | 4 | Chief Business Officer | 24 Feb 2023, 17:22 |
| SYRE | Aeglea BioTherapeutics, Inc. | 23 Aug 2022 | 1 | $0 | 4 | Chief Business Officer | 25 Aug 2022, 19:35 |
| SYRE | Aeglea BioTherapeutics, Inc. | 08 Jun 2022 | 1 | +$20,022 | 4 | Chief Commercial Officer | 10 Jun 2022, 18:24 |
| SYRE | Aeglea BioTherapeutics, Inc. | 17 Feb 2022 | 1 | $0 | 4 | Chief Commercial Officer | 22 Feb 2022, 15:51 |